Kaken Pharmaceutical Co., Ltd.

As of March 31, 2026, Kaken Pharmaceutical Co., Ltd. carries a market capitalization of 156.77B, placing it among publicly traded companies globally. Its enterprise value stands at 109.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kaken Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 9, 2026.

As of March 31, 2026, Kaken Pharmaceutical Co., Ltd. has 37.87M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Kaken Pharmaceutical Co., Ltd. maintains a current ratio of 4.52, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Kaken Pharmaceutical Co., Ltd.'s stock has gained approximately 4.10% over the past 52 weeks. The 50-day moving average sits at 3,905.10, while the 200-day moving average is 4,017.43.

As of March 31, 2026, Kaken Pharmaceutical Co., Ltd. holds 50.71B in cash and equivalents against 3.85B in total debt, resulting in a net debt position of -40.86B. Total book value stands at 147.62B, with working capital of 73.25B providing operational flexibility.

Kaken Pharmaceutical Co., Ltd.'s most recent stock split took place on September 28, 2015 with a 2:1 split ratio.